CS
LYEL icon

Credit Suisse’s Lyell Immunopharma LYEL Stock Holding History

Credit Suisse’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$275K Buy
6,163
+352
+6% +$15.1K ﹤0.01% 2847
2023
Q4 		$225K Sell
5,811
-741
-11% -$26.7K ﹤0.01% 2960
2023
Q3 		$193K Sell
6,552
-912
-12% -$43.3K ﹤0.01% 3033
2023
Q2 		$475K Buy
+7,464
New +$413K ﹤0.01% 2804
2023
Q1 		– Hold
0
– -$24 – 3540
2022
Q4 		– Sell
-50
Closed -$4.97K – 3653
2022
Q3 		$7K Buy
50
+47
+1,567% +$6.36K ﹤0.01% 3630
2022
Q2 		$0 Buy
+3
New +$307 ﹤0.01% 4150

Other funds holding LYEL

MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $267M AUM 5.05% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $237M AUM 107.53% 1-Year Est. Return
WA
WuXi AppTec Shanghai, China $19M AUM 20.22% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Credit Suisse's LYEL Position: Q1 2024 in Review

Credit Suisse increased its Lyell Immunopharma (LYEL) stake by 6.1% in Q1 2024, buying an estimated $15.1K and bringing the position to 6,163 shares worth $275K. The position accounts for ﹤0.01% of the portfolio, ranked #2847.

Credit Suisse first reported a position in LYEL in Q2 2022 and has held it in 6 quarters since. The position peaked at $475K in Q2 2023. 127 funds tracked by Wall St. Rank hold LYEL as of Q1 2024.

  • Credit Suisse held 6,163 shares of Lyell Immunopharma worth $275K as of Q1 2024.
  • Credit Suisse bought 352 Lyell Immunopharma shares in Q1 2024, an estimated $15.1K.
  • Lyell Immunopharma made up ﹤0.01% of Credit Suisse's portfolio in Q1 2024, its #2847 holding.
  • Credit Suisse first reported a position in Lyell Immunopharma in Q2 2022 and has held it in 6 quarters since.
  • Credit Suisse's Lyell Immunopharma position peaked at $475K in Q2 2023.
  • 127 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q1 2024.

Based on Credit Suisse's 13F filing for Q1 2024, filed 10 May 2024.